PR83832

SAN DIEGO, Apr. 28, 2020 /PRNewswire=KYODO JBN/--

Invivoscribe, Inc., a global leader in the development and commercialization of

precision diagnostics announced today that they will begin offering coronavirus

COVID-19 testing through their CLIA/CAP, NY State Licensed LabPMM reference

laboratory in San Diego, CA. The diagnostic test can be ordered by healthcare

providers for patients suspected of having COVID-19. Subjects who participate

in testing can also choose to enroll in an ongoing research study designed to

accelerate identification of promising antibody and vaccine candidates using

Invivoscribe's proprietary next-generation sequencing assays and bioinformatics

platform.

Logo - https://mma.prnewswire.com/media/1019746/Invivoscribe_Logo.jpg

About COVID-19 Testing at LabPMM(R)

LabPMM is a world leading reference laboratory that offers molecular diagnostic

and companion diagnostic testing for healthcare providers, hospitals, and in

support of clinical trials. Our COVID-19 test is a qualitative real-time

Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay that detects RNA

template from the SARS-CoV-2 virus. This testing approach is a proven sensitive

method to assess whether a person is infected with the COVID-19 virus.

Acceptable specimen types include nasopharyngeal (NP) and oropharyngeal (OP)

swabs sent in universal transport medium. Invivoscribe can provide collection

kits consisting of NP swabs with UTM to facilitate testing for healthcare

providers who face shortages in access to sampling devices. Further, COVID-19

test subjects can elect to enroll in our blood-based antibody testing study

that leverages data from our internationally standardized assays which are

currently performed in hundreds of clinical laboratories throughout the United

States, Europe, Asia and ROW.

"Our team is excited to support the worldwide efforts in the fight against the

SARS-CoV-2 virus. We recognized a critical need to ramp up testing services to

help mitigate the ongoing disruptions this pandemic has caused. Leveraging our

25 years of experience, we are pleased to offer high quality testing with rapid

turnaround times and support. Our focus is to serve the community by providing

additional critical patient testing which is urgently needed at this time.",

said Dr. Jeffrey E. Miller, CSO & CEO of Invivoscribe and LabPMM. "Further, the

current worldwide availability and use of our proprietary next-generation

immune receptor sequencing assays and bioinformatics software allow us to

rapidly identify and track the immune response in subjects infected with the

SARS-CoV-2 virus. Using these large international datasets we can rapidly

identify specific antibody paratopes generated in response to the virus to

optimize point of care diagnostics and identify the best epitopes for vaccine

production."

About Invivoscribe, Inc. and LabPMM, LLC.

Invivoscribe is a privately-held biotechnology company dedicated to Improving

Lives with Precision Diagnostics(R). Invivoscribe and its wholly-owed LabPMM

clinical laboratories are industry leaders in providing molecular products,

services, and bioinformatic solutions to over 700 clinical laboratories in more

than 160 countries. Invivoscribe has a successful track record of partnerships

with global pharmaceutical companies interested in developing and

commercializing companion diagnostics, and provides expertise in both

regulatory and laboratory services.

COVID-19 test information, requisition forms, and patient consent documents to

allow ancillary testing in support of COVID-19 research currently being

conducted at Invivoscribe and LabPMM can be downloaded by visiting:

https://catalog.invivoscribe.com/product/covid-19-test/. To learn more please

visit: www.invivoscribe.com or email: support@invivoscribe.com.

SOURCE: Invivoscribe, Inc.